Casdin Capital 13F holdings, Q3 2023
Holdings as of September 30, 2023 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 38 US equity positions worth $896.6m in its Q3 2023 13F filing. The largest position was SRPT at 13.7% of the reported book, followed by BLFS and EQRX INC. Against the Q2 2023 filing, it opened 2 new positions, added to 7 and reduced 11 among the top 38 holdings.
What did Casdin Capital own in Q3 2023? Top 38 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2023 |
|---|---|---|---|---|---|---|---|
| 1 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 13.7% | $122.5m | 1,010,330 | -0% | held |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 12.0% | $107.4m | 7,780,000 | 1% | added |
| 3 | EQRX INC | 9.8% | $87.8m | 39,527,669 | 0% | held | |
| 4 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 6.9% | $62.0m | 1,258,166 | 26% | added |
| 5 | RLAY RELAY THERAPEUTICS INC | Healthcare | 6.5% | $58.2m | 6,923,574 | 15% | added |
| 6 | RVMD REVOLUTION MEDICINES INC | Healthcare | 5.6% | $50.1m | 1,810,000 | 0% | held |
| 7 | VERVE THERAPEUTICS INC | 4.4% | $39.2m | 2,954,710 | 25% | added | |
| 8 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 4.2% | $37.3m | 1,178,075 | -8% | reduced |
| 9 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.0% | $35.4m | 200,000 | -29% | reduced |
| 10 | EXK EXACT SCIENCES CORP | Basic Materials | 3.5% | $31.3m | 459,450 | -8% | reduced |
| 11 | SOMALOGIC INC | 3.4% | $30.1m | 12,604,275 | 0% | held | |
| 12 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 3.1% | $27.3m | 1,577,108 | -7% | reduced |
| 13 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.0% | $26.8m | 1,300,000 | 0% | held |
| 14 | MIRATI THERAPEUTICS INC | 2.4% | $21.7m | 498,427 | 1993% | added | |
| 15 | 2655787D BLUEPRINT MEDICINES CORP | 2.1% | $18.7m | 371,378 | -40% | reduced | |
| 16 | TNYA TENAYA THERAPEUTICS INC | 1.8% | $16.3m | 6,381,377 | 0% | held | |
| 17 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.6% | $14.7m | 1,307,349 | 31% | added |
| 18 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.5% | $13.7m | 570,000 | 0% | held |
| 19 | 4D MOLECULAR THERAPEUTICS IN | 1.5% | $13.2m | 1,033,811 | -3% | reduced | |
| 20 | WGS GENEDX HOLDINGS CORP | Healthcare | 1.3% | $11.3m | 3,095,511 | 0% | held |
| 21 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 1.2% | $10.9m | 2,360,129 | -6% | reduced |
| 22 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 1.0% | $8.6m | 1,035,859 | – | new |
| 23 | AVIDITY BIOSCIENCES INC | 0.9% | $8.0m | 1,250,000 | 47% | added | |
| 24 | 2SEVENTY BIO INC | 0.9% | $7.9m | 2,023,913 | 0% | held | |
| 25 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.7% | $6.4m | 3,206,380 | 0% | held |
| 26 | MXCT MAXCYTE INC | 0.7% | $5.9m | 1,890,000 | -60% | reduced | |
| 27 | FATE FATE THERAPEUTICS INC | Healthcare | 0.5% | $4.3m | 2,050,000 | 0% | held |
| 28 | PRME PRIME MEDICINE INC | 0.4% | $3.5m | 367,175 | 0% | held | |
| 29 | LAB STANDARD BIOTOOLS INC | Healthcare | 0.4% | $3.5m | 1,200,000 | 0% | held |
| 30 | ILMN ILLUMINA INC | Healthcare | 0.4% | $3.4m | 25,000 | -84% | reduced |
| 31 | SANA SANA BIOTECHNOLOGY INC | Healthcare | 0.3% | $2.9m | 750,000 | 0% | held |
| 32 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $2.4m | 510,882 | 0% | held | |
| 33 | ABSI ABSCI CORPORATION | 0.1% | $1.3m | 973,260 | -29% | reduced | |
| 34 | EXSCIENTIA PLC | 0.1% | $966.8k | 213,900 | 0% | held | |
| 35 | CDXS CODEXIS INC | Healthcare | 0.1% | $567.0k | 300,000 | – | new |
| 36 | SINGULAR GENOMICS SYSTEMS IN | 0.1% | $504.4k | 1,323,885 | -2% | reduced | |
| 37 | LIANY LIANBIO | 0.0% | $307.6k | 206,415 | 0% | held | |
| 38 | KRONOS BIO INC | 0.0% | $161.0k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.